Restatement of Previously Issued Consolidated Financial Statements, Consolidated Statements of Operations (Details) - USD ($)	3 Months Ended				6 Months Ended	9 Months Ended	12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2021	Dec. 31, 2020
Consolidated Statements of Operations: [Abstract]
Income tax provision	$ (80,000)	$ 16,000	$ 232,000	$ 252,000	$ 484,000	$ 500,000	$ 420,000	$ 323,000
Net loss	296,000	352,000	617,000	(292,000)	325,000	677,000	973,000	(533,000)
Net loss attributable to noncontrolling interests	92,000	0	0	0	0	0	92,000	0
Net loss attributable to U.S. NeuroSurgical Holdings, Inc.	$ 204,000	$ 352,000	$ 617,000	$ (292,000)	$ 325,000	$ 677,000	$ 881,000	$ (533,000)
Basic net loss per share attributable to U.S. Neurosurgical Holdings, Inc. (in dollars per share)	$ (0.03)	$ (0.05)	$ (0.08)	$ 0.04	$ (0.04)	$ (0.09)	$ (0.11)	$ 0.07
Diluted net loss per share attributable to U.S. Neurosurgical Holdings, Inc. (in dollars per share)	$ (0.03)	$ (0.05)	$ (0.08)	$ 0.04	$ (0.04)	$ (0.09)	$ (0.11)	$ 0.07
Amount Previously Reported [Member]
Consolidated Statements of Operations: [Abstract]
Income tax provision							$ 120,000
Net loss							674,000
Net loss attributable to noncontrolling interests							47,000
Net loss attributable to U.S. NeuroSurgical Holdings, Inc.							$ 627,000
Basic net loss per share attributable to U.S. Neurosurgical Holdings, Inc. (in dollars per share)							$ (0.08)
Diluted net loss per share attributable to U.S. Neurosurgical Holdings, Inc. (in dollars per share)							$ (0.08)